GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Asset Impairment Charge

Myriad Genetics (HAM:MYD) Asset Impairment Charge : €52.6 Mil (TTM As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Asset Impairment Charge?

Myriad Genetics's Asset Impairment Charge for the three months ended in Mar. 2025 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €52.6 Mil.

Myriad Genetics Asset Impairment Charge Historical Data

The historical data trend for Myriad Genetics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Asset Impairment Charge Chart

Myriad Genetics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.53 1.59 15.95 - 54.05

Myriad Genetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 10.13 0.63 41.83 -

Myriad Genetics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €52.6 Mil.

Myriad Genetics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Asset Impairment Charge
Comparable Companies
CSTL FLGT CDNA PSNL STIM ATLN OPK NEOG LDDD ACRS TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
MYGN:USA 0K3W:UK MYD:Germany
Address
322 North 2200 West, Salt Lake City, UT, USA, 84116
Website
https://www.myriad.com
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.